AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01597076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iridoid enriched mixed fruit beverage
Description: Mixed fruit beverage consisting of noni (Morinda citrifolia) juice, Cornelian cherry (Cornus mas \& Cornus officinalis) puree and juice, olive (Olea europea) leaf extract, and other fruit juices and natural flavors
Study NCT01450566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Use of lidocaine
Study NCT01450566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline
Study NCT03288558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A comprehensive perioperative mechanical ventilation strategy
Description: 1) Intervention group.~* Recruitment maneuvers (doubling the tidal volumes for 10 consecutive breaths) every 30min and after every time mechanical ventilation is stopped for surgical reasons, suctioning occurs or the breathing circuit is disconnected~* Mechanical ventilation will be continued during CPB (PEEP 5 cm H2O, respiratory rate 8/min, Tidal Volume 6 ml/kg PBW, FiO2 21%~* Avoidance of lung de-recruitment during patient's transfer (use of PEEP via PEEP valves, endotracheal tube clamps during disconnection from the breathing circuit)~* Avoidance of disconnection from respiratory circuit during respiratory secretions suctioning (applying closed suction circuits)~* For the remaining aspects the mechanical ventilation settings will be the same as in the control group.~Tidal volume 6ml/kg PBW PEEP 5cm H20 FiO2 to target SatO2 of 92-97% Discontinuation of mechanical ventilation during cardiopulmonary bypass
Study NCT01632345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Part I: Doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) depending upon randomization, taken orally every morning with or without food for at least 24 weeks. Part II: Selected dose of doravirine depending upon randomization (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet orally every morning with or without food for 96 weeks.
Study NCT01632345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Efavirenz 600 mg tablet orally at bedtime taken without food on an empty stomach for 96 weeks
Study NCT01632345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRUVADA®
Description: Open-label TRUVADA® (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning for 96 weeks
Study NCT01632345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRUVADA®
Description: Open-label TRUVADA® (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning for 96 weeks
Study NCT01632345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Doravirine
Description: Placebo tablets matching doravirine
Study NCT01632345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Efavirenz
Description: Placebo tablets matching efavirenz
Study NCT03986671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transmembrane EMG Oropharynx Probe
Description: Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmembrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
Study NCT04399434 — intervention group
Intervention type: OTHER
Intervention: test gut microbiota, SCFAs and glucolipid metabolism and insulin sensitivity
Description: test gut microbiota and SCFAs in mothers and their newborns and glucolipid metabolism and insulin sensitivity in mothers
Study NCT02132312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS302
Study NCT02132312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine HCl
Study NCT02860572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: follow-up without intervention
Study NCT02860572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluid bolus
Study NCT03229668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule administered 1 hour prior to the surgical operation
Study NCT03229668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Oral Capsule [Lyrica] 75mg
Description: Pregabalin Oral Capsule \[Lyrica\] 75 mg administered 1 hour prior to the surgical operation
Study NCT03229668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Oral Capsule [Lyrica] 150 mg
Description: Pregabalin Oral Capsule \[Lyrica\] 150 mg administered 1 hour prior to the surgical operation
Study NCT03683758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIFA11+
Description: The FIFA11+ has three parts and consist of 15 exercises.~Part 1 consists of active stretching, running and controlled partner contact drills.~Part 2 has three difficulty levels for 6 sets of exercises. The exercises consist of core and leg strength exercises, balance and plyometric drills. The exercises in this section are perhaps the most unique element to the FIFA11+ warm-up, as strength-specific exercises like the Nordic Hamstring Curl are not generally included in soccer warm-ups.~Part 3 consists of higher intensity running drills, compared to those covered in Part 1.~Unlike many soccer warm-ups, the FIFA11+ has been studied rigorously in terms of its injury reduction potential.
Study NCT03683758 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 'Usual' Soccer Warm-up
Description: This warm-up is time-matched to the FIFA11+ (approximately 20 minutes) and is considered 'usual' for the team.~This warm-up consists of stretching, running and agility drills, in addition to small sided games with a soccer ball, which is not a part of the FIFA11+.~The 'usual' warm-up is decided by the coach with no standardization nor any formal research on its effectiveness in injury reduction or performance enhancement.
Study NCT04594928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667
Description: GLPG3667 capsules
Study NCT04594928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study NCT04241263 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wireless vital sign monitoring - comparative
Description: Participants who currently have vital sign monitoring will, in addition, have the wireless system attached. We will then collect up to 24 hours of vital sign data from both systems, which will allow us to make direct comparisons between them.
Study NCT04241263 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wireless vital sign monitoring - usability
Description: Babies will be recruited who do not currently require vital sign monitoring. The wireless system will be attached to these babies by nurses who have been trained in its use. A parent will then be asked to perform Kangaroo Care for as long as they feel comfortable. After the baby is placed back in its cot, and the sensors have been removed, we will conduct (separate) interviews with the nurse and the parent on the neonatal intensive care unit (NICU).
Study NCT00619307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif New Formulation + prophylactic Ibuprofen
Description: Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, receives systematically 400 mg ibuprofen as prophylactic treatment against flu-like symptoms on days when Rebif New Formulation 44 mcg three times a week is injected
Study NCT00619307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif New Formulation + ibuprofen PRN
Description: Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, should not administer Ibuprofen before the first Rebif New Formulation injection. If flu-like symptoms occur after the 44 mcg Rebif New Formulation injection then the subject can administer 400 mg ibuprofen. This should only be administered after the Rebif New Formulation injection and not before the Rebif New Formulation injection.
Study NCT02215304 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium longum ssp infantis R0033
Description: 12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)
Study NCT02215304 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus helveticus R0052
Description: 12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)
Study NCT02215304 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium bifidum R0071
Description: 12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)
Study NCT02215304 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)
Study NCT01781559 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: phenolic acid
Description: phenolic acid
Study NCT01781559 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: phenolic acid
Description: phenolic acid
Study NCT01781559 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phenolic acid
Description: phenolic acid
Study NCT01835730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PE0139 Injection
Study NCT01835730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02157077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intravitreal Injection
Study NCT03890367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine
Description: Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular
Study NCT03890367 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine
Description: Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Intramuscular
Study NCT03890367 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal group C polysaccharide Conjugate vaccine adsorbed
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT02123576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxyfylline
Study NCT02123576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02123576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMO Therapy
Description: Albumin, midodrine and octreotide therapy (standard of care for HRS)
Study NCT02123576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMO Therapy
Description: Albumin, midodrine and octreotide therapy (standard of care for HRS)
Study NCT03586115 — intervention group
Intervention type: DEVICE
Intervention: Critical flicker frequency assessment
Description: All patients will undergo critical flicker frequency assessment to evaluate the presence of minimal hepatic encephalopaty. In addition, hepatic elastometry will be assessed to evaluate the presence of advanced liver fibrosis.
Study NCT02386501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADXS31-164
Study NCT00997594 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Radiofrequency (RF) ablation was done after RF electrodes were placed in the adrenal tumor in the adrenal RF ablation group. RF ablation was done after RF electrodes were placed in the targeted abdominal tumors other than adrenal gland in the abdominal RF ablation other than adrenal gland group.
Study NCT03172130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Straight CPAP
Study NCT03172130 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CPAP
Study NCT03720470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-04965842 100 mg
Description: PF-04965842 100 mg, administered as two tablets to be taken orally once daily as follows:~1. In the arm PF-04965842 100 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 100 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~2. In the arm Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 subjects take PF-04965842 100 mg from Week 16 to Week 20.
Study NCT03720470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 100 mg
Description: PF-04965842 100 mg, administered as two tablets to be taken orally once daily as follows:~1. In the arm PF-04965842 100 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 100 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~2. In the arm Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 subjects take PF-04965842 100 mg from Week 16 to Week 20.
Study NCT03720470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-04965842 200 mg
Description: PF-04965842 200 mg, administered as two tablets to be taken orally once daily as follows:~1. In the arm PF-04965842 200 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 200 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~2. In the arm Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842 subjects take PF-04965842 200 mg from Week 16 to Week 20.
Study NCT03720470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 200 mg
Description: PF-04965842 200 mg, administered as two tablets to be taken orally once daily as follows:~1. In the arm PF-04965842 200 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 200 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~2. In the arm Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842 subjects take PF-04965842 200 mg from Week 16 to Week 20.
Study NCT03720470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Two subcutaneous injections of Dupilumab 300 mg as a loading dose administered on Day 1 (for a total of 600 mg) followed by one injection once every two weeks (q2w) until Week 16.
Study NCT03720470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Placebo
Description: Oral placebo (for PF-04965842) administered as two tablets to be taken orally once daily as follows:~1. In the arm Dupilumab Injection + Oral Placebo followed by Oral Placebo, the Oral Placebo is taken together with Dupilumab from Day 1 until Week 16, then by itself to Week 20;~2. In the arms Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 and Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842, subjects, take Oral Placebo from Day 1 until Week 16.
Study NCT03720470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Oral placebo (for PF-04965842) administered as two tablets to be taken orally once daily as follows:~1. In the arm Dupilumab Injection + Oral Placebo followed by Oral Placebo, the Oral Placebo is taken together with Dupilumab from Day 1 until Week 16, then by itself to Week 20;~2. In the arms Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 and Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842, subjects, take Oral Placebo from Day 1 until Week 16.
Study NCT01515813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin sodium
Description: One 40 mg tablet of Pravastatin sodium taken orally once daily.
Study NCT01515813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
Description: Participant will be administered one tablet of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)600 mg/200 mg/300 mg taken orally once daily
Study NCT01515813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin sodium
Description: Two 40mg tablets (80 mg total) of Pravastatin sodium taken orally once daily.
Study NCT01579630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500mg/m2 iv
Description: EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
Study NCT01579630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500mg/m2 iv and Gefitinib 250 mg
Description: EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
Study NCT03667690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezafungin for Injection
Description: Intravenous antifungal therapy
Study NCT03252730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WO 4260 Cosmetic Product for Topical Use
Description: Application on the hair scalp at least once a day over four weeks
Study NCT02027532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Study NCT03667690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin
Description: Intravenous antifungal therapy
Study NCT03667690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Oral antifungal therapy
Study NCT03667690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous placebo
Description: Normal saline
Study NCT03667690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral placebo
Description: Microcrystalline cellulose
Study NCT00528996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR
Description: Solution
Study NCT03720470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injectable Placebo
Description: Two subcutaneous injections of Placebo (for Dupilumab) administered as a loading dose on Day 1 followed by one injection every other week (q2w) until Week 16.
Study NCT00528996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide
Description: Solution
Study NCT00528996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution
Study NCT04584242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gluconon tab 15mg
Description: frosting and formulation : a round, convex tablet of white to gray. path of administration : once a day, two tabs, oral Amount of raw material medication (1 pill) : Pioglitazone hydrochloride 16.53mg storage method : Store 15 to 30°C to avoid light-tight containers and moisture manufacturing source : DONG-A ST
Study NCT04584242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suganon tab 5mg
Description: frosting and formulation : pink circular film coating tablets path of administration : once a day, one tabs, oral Amount of raw material medication (1 pill) : Evogliptin tartrate 6.869mg(5mg as evogliptin) storage method : Confidential containers, stored at room temperature (1-30°C) manufacturing source : DONG-A ST
Study NCT04150952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRV-based training
Description: Intervention based on HRV-guided training for the performance improvement of athletes. Pre-competitive HRV, subjective effort perception, anxiety and mood will also be analysed.
Study NCT04150952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TRAD training
Description: Traditional endurance training
Study NCT03665584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FxCO2 Laser
Description: The FxCO2 laser allows a microablative effect in soft tissue.
Study NCT03665584 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser
Description: The Sham laser will be used on the participants who receive the sham treatment.
Study NCT03720470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable Placebo
Description: Two subcutaneous injections of Placebo (for Dupilumab) administered as a loading dose on Day 1 followed by one injection every other week (q2w) until Week 16.
Study NCT01003509 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: modified shouldice and double
Description: one arm modified shouldice, other one is double repair
Study NCT01237873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ali/Amlo 150/2.5 mg
Description: Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg